Here's Why Editas Could Beat Intellia to a CRISPR Therapy

Breakthrough genome editing companies including Editas (NASDAQ:EDIT) and Intellia Therapeutics (NASDAQ:NTLA) have been in a tailspin since late 2019, and the latest earnings reports from both of those companies show that their revenue from collaborations and partnerships has started to dry up despite positive revenue growth overall.